Emerging Market Earnings Roundup: China Surpasses Japan As AstraZeneca’s Second Largest Market (Part 4)
This article was originally published in PharmAsia News
China is now AstraZeneca’s second largest market where it out grew multinational peers including Pfizer in the first quarter.
You may also be interested in...
AstraZeneca did not address rumors it has become an acquisition target of Pfizer during its first quarter conference call. CEO Soriot did say that some mega-mergers can work, but such deals have to be evaluated on a case-by-case basis.
Increasingly looking to China to commercialize their latest therapies, multinationals may be leaping into unknown waters to navigate an intellectual property judiciary and administrative maze, in a country where some copy drugs have been approved before patent expiry. With a government trying to balance innovation and access, two recent rulings involving AstraZeneca shed rare light onto China’s protections for innovation, with advisors pointing to challenges and success factors.
SinoVac’s rapid antibody response, CanSino’s easier logistics requirements - plus cost advantages - make Chinese developers optimistic about supplying the world with COVID vaccines.